SOUTH SAN FRANCISCO, Calif. (AP) _ CytomX Therapeutics Inc. (CTMX) on Wednesday reported a loss of $13.4 million in its second quarter.

The South San Francisco, California-based company said it had a loss of 35 cents per share.

The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 34 cents per share.

The biopharmaceutical company posted revenue of $21.3 million in the period, which beat Street forecasts. Four analysts surveyed by Zacks expected $16.5 million.

CytomX Therapeutics shares have increased 20 percent since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $25.40, an increase of 72 percent in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CTMX at https://www.zacks.com/ap/CTMX